Paper Details

  1. Home
  2. Paper Details

Synergic effects of the cyclin-dependent kinase (CDK) inhibitor olomoucine and androgen-antagonist bicalutamide on prostatic cancer cell lines.

Author: BouchalJ, HlobilkováA, KnillováJ, KolárZ, StrnadM

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The combination of olomoucine and bicalutamide was more effective than either drug alone in reducing the growth of prostate cancer cells. These drugs may be helpful for treating prostate cancer in the future.
Paper Details　
Original Abstract of the Article :
Currently, mechanisms leading to both apoptosis induction and the development of hormone-independence of prostate carcinoma cells are intensively studied. Attention is also given to the possibility of restoring cell sensitivity to hormone-antagonists. The present study focuses on the effect of the c...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/15640940

データ提供：米国国立医学図書館（NLM）

A Synergistic Approach to Prostate Cancer: Combining Forces

This study investigates the potential of combining olomoucine, a cyclin-dependent kinase (CDK) inhibitor, and bicalutamide, an androgen-antagonist, for the treatment of prostate cancer. The researchers examined the synergistic effects of these two drugs on both hormone-sensitive and hormone-insensitive prostate cancer cell lines, seeking to develop more effective treatment strategies for this challenging disease.

A Powerful Combination: Targeting Multiple Pathways

The study found that combining olomoucine and bicalutamide significantly reduced cell viability in both hormone-sensitive and hormone-insensitive prostate cancer cell lines, like a desert explorer using a combination of tools to navigate the challenging terrain. This finding suggests that this synergistic approach could be a valuable tool for the treatment of prostate cancer.

Living with Prostate Cancer: A Journey of Hope

This study offers a glimmer of hope for patients battling prostate cancer, like a well in the desert, providing a source of relief and a path towards a brighter future. The synergistic combination of olomoucine and bicalutamide could pave the way for more effective and personalized therapies, improving outcomes for individuals facing this challenging disease.

Dr.Camel's Conclusion

This study highlights the power of combination therapy in the fight against cancer. By combining forces and targeting multiple pathways, researchers can develop more effective treatments. It's a journey of collaboration and innovation, where we continue to explore new avenues for conquering cancer and improving the lives of those affected.
Date :
  1. Date Completed 2005-02-17
  2. Date Revised 2016-11-24
Further Info :

Pubmed ID

15640940

DOI: Digital Object Identifier

15640940

Related Literature

Article Analysis
・Effects of bicalutamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.